Puma Biotechnology PBYI
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
PBYI at a glance
Shares of Puma Biotechnology are down 0.98% at $7.05. The company is worth $364.47M, number 3692 out of 3753 on our list.
Over the past 52 weeks it has traded between $4.84 and $11.50, so it sits 38.7% below the top of that range. Holders are ahead 44.2% over twelve months, but down 22.7% across the last three months.
On the chart it has slipped under both the 50-day ($9.54) and 200-day ($8.04) moving averages; RSI is 24, which some call oversold, and the last 30 sessions moved at roughly 69% annualized volatility.
For the quarter ended Sep 2026 it reported $55.06M in revenue, up 1.1% from a year earlier, with $5.96M of net profit (a 10.3% margin).
The stock changes hands at 15.3 times trailing earnings, 4,616% above its five-year average of 0.3. The median for its industry group is 17.1.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Key statistics
Quote as of Nov 21, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
BeStock Grade
Composite of 2 factors below, ranked against the 3734 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
Six-factor research snapshot
Overall percentile: 86.4 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.
| Factor | Percentile |
|---|---|
| Valuation | 36.7 |
| Growth | 73.8 |
| Profitability | 89.0 |
| Momentum | 49.9 |
| Financial health | 70.0 |
| Analyst view | — |
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Morningstar’s fair value model puts the stock at $8.04, so shares trade 12.3% below that estimate. On earnings multiple, it sits in the 76th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -21.1% | Bearish |
| Price vs 50-day average | -26.1% | Bearish |
| Price vs 200-day average | -12.3% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 24.5 | Neutral |
| MACD (12,26,9) | -0.81 | Bearish |
| Bollinger band position | 18% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
How PBYI ranks on BeStock
Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 15.3x earnings, PBYI looks about mid-pack against the market, and trades 10% below the 17.1x median among Biotechnology names. The two comparisons do not always agree.
BeStock Momentum
PBYI is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on PBYI.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Community Sentiment on PBYI
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
PBYI stock: common questions
Where is PBYI trading right now?
$7.05 is the latest print for PBYI, a move of -0.98% against yesterday's close of $7.12. Today's low and high so far: $6.91 and $7.22.
How big is Puma Biotechnology?
Equity value comes to $364.47M at the current price. By that measure it is number 3692 of the 3753 names in our coverage.
What multiple of earnings does PBYI sell for?
Buyers pay 15.3 times the last twelve months of profit (EPS $0.61). Averaged over five years the multiple has been 0.3, and today's level ranks in the 76th percentile of its own history.
How far is PBYI from its yearly high?
The year's floor is $4.84 and the ceiling $11.50. Shares are 38.7% away from that ceiling.
Are there dividends on Puma Biotechnology shares?
Our data shows no dividend paid by Puma Biotechnology over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on PBYI.
Sign in to join the discussion.